RETROPHIN, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 (Exact name of registran ...

1 Corporate Overview Delivering Life-Changing Therapies to People Living with Rare Diseases March 2019 Forward-Looking Statements This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forward-looking statements may be accompanied by such words as ...

Retrophin, Inc. (RTRX) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Chris Cline - VP, IR Eric Dube - CEO Dr. Noah Rosenberg - CMO Laura Clague - CFO Neil McFarlane - COO Dr. Bill Rote - SVP, R&D Conference Call Participants Tim Lugo - William Blair Maury Raycroft - Jefferies Joseph Schwartz - SVB Leerink Keith Tapper - BMO Capital Markets Michelle Gilson - Canaccord Genuity Lisa Bayko - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Ret ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES Commission File Number: 001-36257 RETROPHIN, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-4842691 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ide ...

1 Corporate Overview Delivering Life-Changing Therapies to People Living with Rare Diseases January 2019 Forward-Looking Statements This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forward-looking statements may be accompanied by such words a ...